← All trials
NCT06908434
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2025
- Primary completion
- Dec 31, 2027
- Completion date
- Oct 31, 2028
- First posted
- Apr 3, 2025
- Last posted
- Apr 3, 2025
- Enrollment
- 82
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GeneScience Pharmaceuticals Co., Ltd.Lead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.